Pioneer in Molecular Biology: Conformational Ensembles in Molecular Recognition, Allostery, and Cell Function DOI
Ruth Nussinov

Опубликована: Янв. 1, 2024

Язык: Английский

Molecular principles underlying aggressive cancers DOI Creative Commons
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 16, 2025

Язык: Английский

Процитировано

3
Pioneer in Molecular Biology: Conformational Ensembles in Molecular Recognition, Allostery, and Cell Function DOI Creative Commons
Ruth Nussinov

Journal of Molecular Biology, Год журнала: 2025, Номер unknown, С. 169044 - 169044

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Impact of psychiatric disorders on the risk of glioma: Mendelian randomization and biological annotation DOI Creative Commons

Yanmei Qiu,

Guohao Liu,

Jingwen Li

и другие.

Journal of Affective Disorders, Год журнала: 2024, Номер unknown

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

0
Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery DOI Creative Commons
Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Окт. 15, 2024

Abstract While anticancer drug discovery has seen dramatic innovations and successes, sequential single therapies are time-limited by resistance, combinatorial strategies have been lagging. The number of possible combinations is vast. To select the oncologist requires knowledge optimal combination proteins to co-target. Currently, that considers primarily from empirical observations clinical praxis. Our aim develop a signaling-based method discover for co-target with combinations, test it on available, patient-derived data. temper expected resistance regimen, we offer concept-based stratified pipeline aimed at selecting co-targets combinations. strategy unique in its selection being based signaling pathways. This significant since cancer, commonly bypasses blocked wielding alternative, or complementary, routes execute cell proliferation. network-informed approach harnesses advanced network concepts metrics, our compiled, tissue-specific co-existing mutations. Co-existing driver mutations common resistance. Thus, mimic cancer counter scenarios, seeks when targeted can shut off cancer’s modus operandi . That is, parallel complementary pathways would be blocked. Rotating through could further lessen emerging We applied breast colorectal ESR1 | PIK3CA BRAF subnetworks. Consistently, results suggest co-targeting ESR1|PIK3CA subnetwork an alpelisib-LJM716 combination. In they alpelisib, cetuximab, encorafenib Collectively, pipeline’s promising, validated patient-based xenografts. GRAPHICAL ABSTRACT

Язык: Английский

Процитировано

0
Pioneer in Molecular Biology: Conformational Ensembles in Molecular Recognition, Allostery, and Cell Function DOI
Ruth Nussinov

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0